SCHEDULE: Vanguard Discloses 5% Stake in Repligen Corp

Vanguard Capital Management has reported beneficial ownership of 5% of Repligen Corp's common stock as of June 30, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, now beneficially owns 2,825,579 shares of Repligen Corp's common stock.
• This holding represents 5% of the total class of securities.
• The filing indicates Vanguard has sole dispositive power over these shares.
• Vanguard Capital Management is classified as an investment adviser.
• The securities were acquired and are held in the ordinary course of business.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a significant but passive ownership stake by a major institutional investor without providing new operational or financial performance data for Repligen Corp.

Positives

• Vanguard Capital Management's significant stake suggests confidence in Repligen Corp's long-term prospects.
• The filing confirms Vanguard's role as a substantial institutional investor.

Risks

• Potential for future share sales by Vanguard could impact Repligen's stock price.
• Changes in Vanguard's investment strategy could lead to divestment.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Repligen Corp. It solely reports Vanguard's ownership stake.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd."
• "This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power."
• "This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that a Schedule 13G filing by a major institutional investor like Vanguard often signals a passive investment strategy, but a 5% stake is a significant threshold that can attract market attention. This filing provides insight into institutional ownership trends within the biotechnology sector.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's presence, which can be viewed positively, but also introduces potential for future stock movements if Vanguard decides to alter its holdings.
• Management: The filing indicates a stable, passive institutional holder, which generally does not imply direct pressure on management unless the stake changes significantly.

Key Dates

Recommendation

This filing is a routine disclosure of beneficial ownership by a major institutional investor. It does not provide new operational or financial information about Repligen Corp. Therefore, it does not warrant a change in investment strategy based solely on this document; a 'hold' recommendation is appropriate pending further company-specific news.

Keywords

Repligen Corp, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Institutional Investor